New Two-Pronged attack on tough bladder cancer
Disease control
Not yet recruiting
This study is testing a two-part treatment for people with high-risk bladder cancer that has not responded well to the standard BCG therapy. Participants will receive a chemotherapy wash directly into the bladder every 3 weeks, combined with an IV immunotherapy drug every 6 weeks…
Phase: PHASE2 • Sponsor: BLATAM • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC